Endoplasmic reticulum-associated SARS-CoV-2 ORF3a elicits heightened cytopathic effects despite robust ER-associated degradation

IMPORTANCE: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has tragically claimed millions of lives through coronavirus disease 2019 (COVID-19), and there remains a critical gap in our understanding of the precise molecular mechanisms responsible for the associated fatality. One key viral factor of interest is the SARS-CoV-2 ORF3a protein, which has been identified as a potent inducer of host cellular proinflammatory responses capable of triggering the catastrophic cytokine storm, a primary contributor to COVID-19-related deaths. Moreover, ORF3a, much like the spike protein, exhibits a propensity for frequent mutations, with certain variants linked to the severity of COVID-19. Our previous research unveiled two distinct types of ORF3a mutant proteins, categorized by their subcellular localizations, setting the stage for a comparative investigation into the functional and mechanistic disparities between these two types of ORF3a variants. Given the clinical significance and functional implications of the natural ORF3a mutations, the findings of this study promise to provide invaluable insights into the potential roles undertaken by these mutant ORF3a proteins in the pathogenesis of COVID-19.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:15

Enthalten in:

mBio - 15(2024), 1 vom: 16. Jan., Seite e0303023

Sprache:

Englisch

Beteiligte Personen:

Zhang, Jiantao [VerfasserIn]
Cruz-Cosme, Ruth [VerfasserIn]
Zhang, Chenyu [VerfasserIn]
Liu, Dongxiao [VerfasserIn]
Tang, Qiyi [VerfasserIn]
Zhao, Richard Y [VerfasserIn]

Links:

Volltext

Themen:

26S proteasome
Apoptosis
Autophagy
ER and lysosomes
ER stress
ER-associated degradation
Journal Article
Mutant Proteins
NF-kB
ORF3a mutants
ORF3a protein, SARS-CoV-2
Reticulophagy
SARS-CoV-2
TNFα and IL-6
TRIM59
Viroporin Proteins

Anmerkungen:

Date Completed 05.02.2024

Date Revised 10.02.2024

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1128/mbio.03030-23

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM365695602